Ryan Barbara 4

What Happened

• Barbara Ryan, a director of Indivior Pharmaceuticals, was granted 6,518 restricted stock units (RSUs) on May 13, 2026. The Form 4 reports the award at $0.00 per unit (i.e., no cash paid at grant). This is an equity award (compensation), not a market purchase or sale.

Key Details

• Transaction date: 2026-05-13; Form 4 filed: 2026-05-14 (appears timely)
• Transaction type/code: Award/Grant (A); 6,518 RSUs; reported acquisition price $0.00
• Shares owned after transaction: Not specified in this filing
• Footnote: RSUs represent a contingent right to one share each and vest on the day immediately preceding the date of the Issuer’s next annual meeting following the grant, subject to continued service
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted

Context

• RSUs convert to actual shares only after vesting and therefore do not indicate an immediate change in tradable share position. Director RSU grants are commonly part of standard compensation and should be viewed as routine unless accompanied by other trading activity.